Plant-based vaccine candidate against Infectious bursal disease: An alternative to inactivated vaccines for breeder hens

Lucero, María Soledad; Richetta, Matías; Zoth, Silvina Chimeno; Jaton, Juan; Pinto, Silvina; Canet, Zulma Edith; Berinstein, Analía; Gómez, Emma Laura Alfaro

doi:10.1016/j.vaccine.2019.07.069

Cited by 22 publications

(21 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…VP2, the main host-protective antigen of IBDV, is usually used as an immunogen of subunit vaccines to elicit a protective immune response to IBDV [8,32]. Several expression systems, including yeast [33,34], insect cells [35], mammalian cells [29], plant cells [36,37], and E. coli [38] have been used to produce the VP2 of IBDV. Eukaryotic expression systems produce highly bioactive recombinant proteins, but their application is limited by various technical problems, such as low yield and high cost.…”

Section: Discussionmentioning

confidence: 99%

Development of a Viral-Like Particle Candidate Vaccine Against Novel Variant Infectious Bursal Disease Virus

et al. 2021

View full text Add to dashboard Cite

Infectious bursal disease (IBD), an immunosuppressive disease of young chickens, is caused by infectious bursal disease virus (IBDV). Novel variant IBDV (nVarIBDV), a virus that can evade immune protection against very virulent IBDV (vvIBDV), is becoming a threat to the poultry industry. Therefore, nVarIBDV-specific vaccine is much needed for nVarIBDV control. In this study, the VP2 protein of SHG19 (a representative strain of nVarIBDV) was successfully expressed using an Escherichia coli expression system and further purified via ammonium sulfate precipitation and size-exclusion chromatography. The purified protein SHG19-VP2-466 could self-assemble into 25-nm virus-like particle (VLP). Subsequently, the immunogenicity and protective effect of the SHG19-VLP vaccine were evaluated using animal experiments, which indicated that the SHG19-VLP vaccine elicited neutralization antibodies and provided 100% protection against the nVarIBDV. Furthermore, the protective efficacy of the SHG19-VLP vaccine against the vvIBDV was evaluated. Although the SHG19-VLP vaccine induced a comparatively lower vvIBDV-specific neutralization antibody titer, it provided good protection against the lethal vvIBDV. In summary, the SHG19-VLP candidate vaccine could provide complete immune protection against the homologous nVarIBDV as well as the heterologous vvIBDV. This study is of significance to the comprehensive prevention and control of the recent atypical IBD epidemic.

show abstract

Section: Discussionmentioning

confidence: 99%

Development of a Viral-Like Particle Candidate Vaccine Against Novel Variant Infectious Bursal Disease Virus

et al. 2021

View full text Add to dashboard Cite

show abstract

“…The delivery of recombinant proteins as vaccine after inducing expression in plants is an attractive alternative to injectables, especially in developing countries. The oral administration of plant-derived antigens against different diseases has previously been reported by many authors (6,15,(35)(36)(37)(38)(39). The immunogenic response generated against many orally administered proteins of pathogens after expression in transgenic plants (8,33) has encouraged study on the expression of other antigens in plants, with defined goals of edible vaccine development (40).…”

Section: Discussionmentioning

confidence: 99%

“…However, an advantage of subunit vaccine is that requires only immunogenic portion of target virus and reduces the risk of spread and recombination. The major problems related to live and inactivated vaccines are that propagation and inactivation of viruses are expensive due to strict quality controls and sometime improper inactivation could be a major source of disease outbreaks (15,16). Although traditional vaccines are still in use, their application often results in the appearance of symptoms associated with the target disease and failure of animals to respond to the vaccine in field conditions.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Early Stage Development of a Newcastle Disease Vaccine Candidate in Corn

et al. 2020

View full text Add to dashboard Cite

Newcastle disease (ND) is a viral disease that causes labored breathing, periorbital oedema, and ataxia in the majority of avian species. The available vaccines against Newcastle disease virus (NDV) are limited, owing to their low reactivity and multiple dosage requirements. Plant-based machinery provides an attractive and safe system for vaccine production. In the current study, we attempted to express fusion (F) and hemagglutinin-neuraminidase (HN) proteins (the protective antigens against NDV) under constitutive 35S and seed-specific Zein promoters, respectively. Almost 2-7.1-fold higher expression of F gene mRNA in transgenic corn leaves and 8-28-fold higher expression of HN gene mRNA in transgenic corn seeds were observed, when the expression was analyzed by real-time PCR on a relative basis as compared to non-transgenic control plant material (Leaves and seeds). Similarly, 1.66 µg/ml of F protein in corn leaves, i.e., 0.5% of total soluble protein, and 2.4 µg/ml of HN protein in corn seed, i.e., 0.8% of total seed protein, were found when calculated through ELISA. Similar levels of immunological response were generated in chicks immunized through injection of E. coli-produced pET F and pET HN protein as in chickens orally fed leaves and seeds of maize with expressed immunogenic protein. Moreover, the detection of anti-NDV antibodies in the sera of chickens that were fed maize with immunogenic protein, and the absence of these antibodies in chickens fed a normal diet, confirmed the specificity of the antibodies generated through feeding, and demonstrated the potential of utilizing plants for producing more vaccine doses, vaccine generation at higher levels and against other infectious diseases.

show abstract

“…Exposure of birds to the IBDV-contaminated farm causes the rapid spread of the disease [8][9][10]. Due to the significant economic impact of IBD on the poultry industry, traditional and next-generation vaccines including viral vectors, subunit and genetically-engineered vaccines, have been developed to prevent the disease [11][12][13][14].…”

Section: Introductionmentioning

confidence: 99%

Characterization and Inactivation of Infectious Bursal Disease Virus for Use as a Vaccine and Immunodiagnostic Reagent

Ebrahimi

Shahsavandi

Ghodsian

2020

vacres

View full text Add to dashboard Cite

Introduction: Poultry vaccines are used to immunize chickens against different diseases. Inactivated vaccines have been widely used to protect poultry against diseases such as infectious bursal disease (IBD). IBD is one of the most important viral immunosuppressive diseases in the poultry industry. This viral disease targets the immune organs. This study was aimed to evaluate the effect of an inactivated IBDV antigen on inducing the humoral immune response in Specific-Pathogen-Free (SPF) chickens. Methods: An infectious strain of bursal disease virus (IBDV) was isolated from an affected chicken bursa of Fabricius. Serological diagnostic tests and molecular experiments were carried out to identify the isolate. Different concentrations of formalin, beta propiolacton (BPL) and binary ethylenimine (BEI) were used for inactivation of IBDV. The samples of IBDV antigen were adjuvanted separately with ISA-70. Threeweek-old SPF chickens were divided into four groups. Groups 1, 2, and 3 received 0.5 ml of the adjuvanted antigens subcutaneously and group 4 received PBS as negative control. Blood samples from each group were collected 4 weeks post-inoculation and the targets were measured by ELISA and serum neutralization test (SNT). Results: The lowest concentrations that could fully inactivate the infectivity of IBD virus were 2.5 mM for BEI, 0.15% for BPL and 0.1% for formalin. Examination of the inactivated samples with 0.1% formalin showed a decrease in antigenicity after 12 months. Treatment with 2.5 mM BEI and 0.15% BPL showed no apparent adverse effect on IBDV infectivity and showed a reliable inactivation. In the SPF chickens of all experimental groups, the antibody titers raised against IBDV were detected by ELISA. Conclusion: In the group which the virus was inactivated using BEI, the antigenicity stability was much better than others. Hence, BEI-inactivated IBDV is suggested for preparing more immunogenic, efficient and stable vaccines against IBD.

show abstract

Plant-based vaccine candidate against Infectious bursal disease: An alternative to inactivated vaccines for breeder hens

Cited by 22 publications

References 34 publications

Development of a Viral-Like Particle Candidate Vaccine Against Novel Variant Infectious Bursal Disease Virus

Development of a Viral-Like Particle Candidate Vaccine Against Novel Variant Infectious Bursal Disease Virus

Early Stage Development of a Newcastle Disease Vaccine Candidate in Corn

Characterization and Inactivation of Infectious Bursal Disease Virus for Use as a Vaccine and Immunodiagnostic Reagent

Contact Info

Product

Resources

About